

1

2

3

4 A 4-year review of amniocentesis at a tertiary hospital in Ethiopia: an experience
5 from a LMIC

6

7

8 Haile G. Mekuria^{1*}, Hilkiah K. Suga^{2†}, Gadise Bekele³

9

10 ¹Department of Obstetrics and Gynecology, Myungsung Medical College/MCM
11 Comprehensive Specialized Hospital, Addis Ababa, Ethiopia

12 ²Department of Research, Blue Health Medical Consultancy, Addis Ababa, Ethiopia

13 ³Department of Biostatistics, Addis Continental Institute of Public Health, Addis Ababa,
14 Ethiopia

15

16 *First author

17 †Corresponding author: hilkms@gmail.com

18 Abstract

19 Background: Amniocentesis is a technique for withdrawing amniotic fluid from the
20 uterine cavity using a needle via a trans-abdominal approach. It has multiple diagnostic
21 and therapeutic uses such as prenatal genetic studies and amnioreduction for
22 polyhydramnios. The commonest indications are advanced maternal age and increased
23 risk on maternal serum screening. The objective of this study is to review the common
24 indications, outcomes and complications of amniocentesis at a tertiary hospital in
25 Ethiopia.

26 Methods: A retrospective cross-sectional study was conducted at a tertiary hospital in
27 Ethiopia. Data was collected from the Fetomaternal division's log records and follow-up
28 charts during the time period of 2019 to 2022. All records of patients who had
29 amniocentesis done were included in the study. Socio-demographic information and
30 obstetric history and variables related to the procedures were retrieved. Descriptive
31 statistics was done using the software IBM Statistical Package for Social Sciences
32 (SPSS) version 25.

33 Results: A total of 35 patients' records were reviewed. The mean maternal age was 32
34 years (range, 19 – 43 years). The mean gestational age was 20.9 weeks (SD \pm 2.2).
35 The commonest indications for amniocentesis were previous history of Down syndrome
36 (11%), advanced maternal age (9%) and QUAD 1:200 for Down syndrome (6%).
37 Karyotype test was done in 29 of the 35 amniocentesis cases which was normal in 72%
38 of the cases, 17% had Trisomy-21 and 11% had Trisomy-18. Fifty-two percent of the
39 pregnancy had a live full term delivery and 25% of the cases terminated the pregnancy.

40 Conclusion: The most common indications for amniocentesis in Ethiopia were abnormal
41 ultrasound finding, advanced maternal age and abnormal QUAD test results. Around a
42 quarter of the genetic tests which were done after the procedure had chromosomal
43 abnormalities, from which, the majority were terminated. There was no complication
44 related to the procedure.

45 Keywords: amniocentesis, advanced maternal age, prenatal genetic study,
46 chromosomal abnormality, fetomaternal complication

47 Introduction

48 Amniocentesis is a technique for withdrawing amniotic fluid from the uterine cavity using
49 a needle via a trans-abdominal approach. Amniocentesis has been widely used since it
50 was first performed in 1956. Originally reported as a method of determining fetal sex in
51 utero, Fuchs and Riis then hypothesized that it could be possible to diagnose
52 chromosomal abnormalities in utero via this technique. By 1963, it had been confirmed
53 that the karyotype of fetal and amniotic cells are identical (1 – 3).

54 The most common diagnostic indications for obtaining amniotic fluid are prenatal
55 genetic studies and assessment of fetal lung maturity. Other indications include, but are
56 not limited to, evaluation of the fetus for infection, degree of hemolytic anemia, blood or
57 platelet type, hemoglobinopathy, and neural tube defects. Risks include spontaneous
58 abortion, infection, needle injuries, and preterm labor (4, 5).

59 Amniocentesis is also performed as a therapeutic procedure to remove excess amniotic
60 fluid, such as in symptomatic polyhydramnios or twin-twin transfusion syndrome, or to
61 reduce volume and pressure of amniotic fluid in cases of prolapsed fetal membranes in
62 the second trimester to facilitate placement of an emergency cerclage.(6, 7)

63 Since the late 1960s, amniocentesis has become a widely accepted method of
64 obtaining fetal genetic information (8). Amniocentesis for prenatal genetic studies is
65 technically possible at any gestational age after approximately 11 weeks of gestation,
66 but is optimally performed after 15 to 17 weeks of gestation. Procedures performed
67 before 15 weeks (ie, early amniocentesis) are associated with higher fetal loss and
68 complication rates, including culture failure, and should be avoided. Later procedures

69 can be problematic if termination of pregnancy is planned based upon abnormal results.
70 Although some pain is associated with amniocentesis, it is generally well tolerated
71 without the need for anesthesia (8, 9).

72 Maternal age over 35 is the most common indication for amniocentesis (10). It is
73 conventionally performed between 16 – 24 weeks. The chances of late-onset
74 abnormalities after 1st and 2nd-trimester ultrasound examinations are estimated at
75 5.5%-17% (11).

76 Counseling about the risk and benefit of the procedure is very important as some
77 women may decline the procedure if they don't want to terminate the pregnancy
78 whatever the result is. Others, even if they don't want to terminate the pregnancy, they
79 accept the procedure to prepare themselves for the care of the baby after delivery (12).

80 Prenatal chromosomal microarray analysis is recommended for a patient with a fetus
81 with one or more major structural abnormalities identified on ultrasonographic
82 examination and who is undergoing invasive prenatal diagnosis (13).

83 Even though the procedure is more than 6 decades old, as far as the authors search
84 goes, this report is the first of its kind from an experience located in the Eastern Africa.
85 This study aims to review the common indications and outcomes of prenatal diagnostic
86 amniocentesis and its complications at a tertiary center in Ethiopia.

87 Methods

88 A retrospective cross-sectional study was conducted at the Fetomaternal division,
89 Department of Obstetrics and Gynecology, MCM Comprehensive Specialized Hospital,

90 Addis Ababa, Ethiopia. The department is one of the few in the country that gives
91 prenatal amniocentesis service. Data was collected from the division's log records and
92 follow-up charts which was abstracted from 2019 to 2022. Study period was from June
93 1st to 30th, 2023. Records of all patients who had prenatal amniocentesis done during
94 the timeframe were included in the study. The following variables were collected:
95 indication, maternal age, gestational age, needle size, BMI, pregnancy outcome, result
96 of the genetic test, presence of vaginal bleeding post-procedure, presence of
97 amnionitis. The procedures were carried out by the same fetomaternal specialist using
98 the same ultrasound guided techniques. IBM Statistical Package for Social Sciences
99 (SPSS) version 25 was used to compute descriptive statistics.

100 Ethical approval was obtained prior to the data collection and the investigators did not
101 collect personal identification information of the patients.

102 Results

103 A total of 35 women had amniocentesis between 2019 and 2022 with the mean
104 maternal age was 32 years (range, 19 – 43 years). The mean gestational age was 20.9
105 weeks (SD \pm 2.2, range 17 – 25) and mean maternal BMI was 21 kg/m² (SD \pm 2.4). In
106 23 patients, 20 Gauge needle was used and 22 Gauge was used in the others. The
107 needle insertion to the probe angle was perpendicular in 30 of the procedures (85%)
108 and parallel in 5 of the procedures (15%).

109 The commonest indications were previous history of down syndrome (11%), advanced
110 maternal age (9%), cleft lip (6%), history of Recurrent pregnancy loss or RPL (6%),

111 hydrocephalus (6%), non-immune hydrops (6%), omphalocele (6%), QUAD 1:200 for
112 down syndrome (6%).

113 Karyotype test was done in 29 of the 35 amniocentesis cases. Karyotype results were
114 normal in 72% of cases (21/29), Trisomy-21 in 17% (5/29) and Trisomy-18 in 11%
115 (3/29). Almost half (52%) of the cases had a live birth, 46% (16/35) had a term delivery
116 and 6% (2/35) had a preterm delivery. Stillbirth or miscarriage occurred in 17% (6/35),
117 25% (9/35) of the cases terminated the pregnancy and the outcome was not known in
118 6% (2/35) of the cases. Pathological ultrasonography has the highest positive detection
119 rate (30%)

120 Discussion

121 Amniocentesis is generally done after the 15th gestational week with a miscarriage risk
122 of less than 1% (14, 15). The risk of spontaneous fetal losses following amniocentesis
123 performed before this gestational age increases (16). Likewise, the patients in our study
124 were between the gestational age of 17 and 25 weeks, which were under the accepted
125 gestational age range.

126 Currently twenty and twenty-two gauge needles are commonly used and in this study,
127 two-third of the procedure was done using a 20G needle. The larger needle size i.e.
128 20G is associated with significantly shorter duration of amniocentesis. However, there is
129 no significant difference in the intrauterine bleeding at the insertion site and fetal loss
130 (17, 18). Likewise, none of the patients in this study had documented intrauterine
131 bleeding in both groups (20G vs 22G).

132 A study done in South East China that did a retrospective analysis on more than 4700
133 patients who had an amniocentesis showed the commonest indications for
134 amniocentesis were increased risk on maternal serum screenings and advanced
135 maternal age. They are indications for 86% of the procedures (5). Another 5 year
136 reviews from Malaysia and China hospitals showed similar findings i.e. both indications
137 accounted for more than half of the total procedures (19, 20). Other common indications
138 include poor obstetric history, pathological ultrasonography findings and positive results
139 from non-invasive prenatal testing. However, in our study, the majority of indication for
140 amniocentesis was done due to the pathological ultrasonography findings (57% vs 12%
141 or 4%) followed by previous Down syndrome baby and increased risk on maternal
142 serum screenings, each accounted for 11% of the procedures. Advanced maternal age
143 was an indication in only 9% of cases.

144 Positive detection rate of pathological ultrasonography for chromosomal abnormalities is
145 less than 15% (19, 20). Noninvasive prenatal DNA testing has the highest positive
146 detection rate with greater than 40% (42% and 53%). In our study, pathological
147 ultrasonography has the highest positive detection rate (30%).

148 Conclusion

149 A review of the first 5 years of amniocentesis at our center showed that the most
150 common indication to the procedure was abnormal ultrasound finding. Advanced
151 maternal age and abnormal QUAD test results were also among the common
152 indications. Around a quarter of the genetic tests which were done after the procedure
153 had chromosomal abnormalities, from which, the majority were terminated. There was

154 no complication related to the procedure. Further study is required to understand more
155 fetomaternal complications of amniocentesis in Ethiopia.

156 Reference

- 157 (1) FUCHS F, RIIS P. Antenatal sex determination. *Nature*. 1956 Feb 18;177
158 (4503):330. doi: 10.1038/177330a0. PMID: 13297032.
- 159 (2) Connolly KA, Eddleman KA. Amniocentesis: A contemporary review. *World J Obstet*
160 *Gynecol* 2016; 5(1): 58-65 [DOI: 10.5317/wjog.v5.i1.58]
- 161 (3) Steele MW, Breg WR Jr. Chromosome analysis of human amniotic-fluid cells.
162 *Lancet*. 1966 Feb 19;1(7434):383-5. doi: 10.1016/s0140-6736(66)91387-0. PMID:
163 4159775.
- 164 (4) Bornstein E, Lenchner E, Donnenfeld A, Barnhard Y, Seubert D, Divon MY.
165 Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit
166 analysis based on a large database reflecting the current common practice. *J Perinat*
167 *Med*. 2009;37(2):99-102. doi: 10.1515/JPM.2009.032. PMID: 18999912.
- 168 (5) Tao H, Xiao J, Yang C, Wang J, Tang Y, Guo C, Wang J. Retrospective analysis of
169 4761 cases who underwent amniocentesis in southeast China. *J Obstet Gynaecol*. 2018
170 Jan;38(1):38-41. doi: 10.1080/01443615.2017.1326887. Epub 2017 Aug 1. PMID:
171 28764586.
- 172 (6) Erfani H, Diaz-Rodriguez GE, Aalipour S, Nassr A, Rezaei A, Gandhi M, Mendez-
173 Figueroa H, Aagaard KM, Shamshirsaz AA. Amnioreduction in cases of
174 polyhydramnios: Indications and outcomes in singleton pregnancies without fetal
175 interventions. *Eur J Obstet Gynecol Reprod Biol*. 2019 Oct;241:126-128. doi:
176 10.1016/j.ejogrb.2019.05.019. Epub 2019 May 19. PMID: 31160132.
- 177 (7) Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org;
178 Dashe JS, Pressman EK, Hibbard JU. SMFM Consult Series #46: Evaluation and
179 management of polyhydramnios. *Am J Obstet Gynecol*. 2018 Oct;219(4):B2-B8. doi:
180 10.1016/j.ajog.2018.07.016. Epub 2018 Jul 23. PMID: 30048635.
- 181 (8) Daum H, Ben David A, Nadjari M, Zenvirt S, Helman S, Yanai N, Meiner V, Yagel S,
182 Frumkin A, Shkedi Rafid S; collaborating authors. Role of late amniocentesis in the era
183 of modern genomic technologies. *Ultrasound Obstet Gynecol*. 2019 May;53(5):676-685.
184 doi: 10.1002/uog.20113. Epub 2019 Apr 12. PMID: 30155922.
- 185 (9) Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. *Obstet*
186 *Gynecol*. 2016 May;127(5):e108-e122. doi: 10.1097/AOG.0000000000001405. PMID:
187 26938573.

- 188 (10) Papp C, Papp Z. Chorionic villus sampling and amniocentesis: what are the risks in
189 current practice? *Curr Opin Obstet Gynecol*. 2003 Apr;15(2):159-65. doi:
190 10.1097/00001703-200304000-00011. PMID: 12634608.
- 191 (11) Quinlan MP. Amniocentesis: indications and risks. *Virtual Mentor*. 2008 May
192 1;10(5):304-6. doi: 10.1001/virtualmentor.2008.10.5.cpr11-0805. PMID: 23211983.
- 193 (12) Bardin R, Hadar E, Haizler-Cohen L, Gabbay-Benziv R, Meizner I, Kahana S,
194 Yeshaya J, Yacobson S, Cohen-Vig L, Agmon-Fishman I, Basel-Vanagaite L, Maya I.
195 Cytogenetic analysis in fetuses with late onset abnormal sonographic findings. *J Perinat*
196 *Med*. 2018 Nov 27;46(9):975-982. doi: 10.1515/jpm-2017-0071. PMID: 28915119.
- 197 (13) Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee
198 Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of
199 Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. *Obstet Gynecol*.
200 2016 Dec;128(6):e262-e268. doi: 10.1097/AOG.0000000000001817. PMID: 27875474.
- 201 (14) Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the
202 fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year
203 experience. *Obstet Gynecol*. 2008 Mar;111(3):589-95. doi:
204 10.1097/AOG.0b013e318162eb53. PMID: 18310360.
- 205 (15) Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage
206 following amniocentesis or chorionic villus sampling: systematic review of literature and
207 updated meta-analysis. *Ultrasound Obstet Gynecol*. 2019 Oct;54(4):442-451. doi:
208 10.1002/uog.20353. Epub 2019 Sep 6. PMID: 31124209.
- 209 (16) Saltvedt S, Almström H. Fetal loss rate after second trimester amniocentesis at
210 different gestational age. *Acta Obstet Gynecol Scand*. 1999 Jan;78(1):10-4. PMID:
211 9926885.
- 212 (17) Athanasiadis A, Petrakis P, Mikos T. Comparison of perinatal outcome after 2nd
213 trimester amniocentesis using 22G and 20G needle. *Hippokratia*. 2017 Jan-
214 Mar;21(1):60. PMID: 29904263; PMCID: PMC5997025.
- 215 (18) Athanasiadis AP, Pantazis K, Goulis DG, Chatzigeorgiou K, Vaitisi V,
216 Assimakopoulos E, Tzeveleki F, Tsalikis T, Bontis JN. Comparison between 20G and
217 22G needle for second trimester amniocentesis in terms of technical aspects and short-
218 term complications. *Prenat Diagn* 2009; 29: 761-765 [PMID: 19412914 DOI:
219 10.1002/pd.2283]
- 220 (19) Jummaat F, Ahmad S, Mohamed Ismail NA. 5-Year review on amniocentesis and
221 its maternal fetal complications. *Horm Mol Biol Clin Investig*. 2019 Sep

222 20;40(2):/j/hmbci.2019.40.issue-2/hmbci-2019-0006/hmbci-2019-0006.xml. doi:
223 10.1515/hmbci-2019-0006. PMID: 31539354.

224 (20) Liu Y, Sun XC, Lv GJ, Liu JH, Sun C, Mu K. Amniotic fluid karyotype analysis and
225 prenatal diagnosis strategy of 3117 pregnant women with amniocentesis indication. J
226 Comp Eff Res. 2023 May 31;12(6):e220168. doi: 10.57264/cer-2022-0168. Epub ahead
227 of print. PMID: 37256256; PMCID: PMC10402904.

228

229

230 Table 1: A five year summary of genetic test results and indications for amniocentesis at
 231 MCM Comprehensive Specialized Hospital, 2019 – 2022

Genetic test result			Number of cases	Percentage (denominator being the subtotal, %)	Percentage (denominator being the grand total, %)
Normal Karyotype	Indication for amniocentesis	Advanced maternal age	2	9.52	5.71
		Pathological ultrasonography findings	12	57.14	34.28
		History of recurrent pregnancy loss	1	4.76	2.86
		Previous history of MR baby	1	4.76	2.86
		Previous hx of Down Syndrome	4	19.05	11.43
		QUAD 1:200 for Down Syndrome	1	4.76	2.86
	Total		21	100	60
Trisomy 21	Indication for amniocentesis	Pathological ultrasonography findings	5	100	14.29
	Total		5	100	14.29
Trisomy 18	Indication for amniocentesis	Pathological ultrasonography findings	1	33.33	2.86
		History of still birth	1	33.33	2.86
		QUAD 1:10 for trisomy 18	1	33.33	2.86
Total		3	100	8.57	

Not determine d	Indication for amniocentesis	Advanced maternal age	1	16.67	2.86
		Pathological ultrasonography findings	2	33.33	5.71
		History of RPL	1	16.67	2.86
		QUAD 1:150 for Down Syndrome	1	16.67	2.86
		QUAD 1:200 for Down Syndrome	1	16.67	2.86
	Total	6	100	17.14	
Grand total			35		100

232

233

234

235 Table 2: Pregnancy outcomes and genetic test results of women who had
236 amniocentesis at MCM Comprehensive Specialized Hospital, 2019 – 2022

		Genetic test result			Total
		Normal	Trisomy 18 or 21	Not determined	
Pregnancy outcome	Term delivery	12	0	4	16
	Preterm delivery	2	0	0	2
	Terminated	1	7	1	9
	Still birth	5	1	0	6
	Unknown	1	0	1	2
Total		21	8	6	35

237